Idiopathic facial aseptic granuloma in children: Management and long-term follow-up.
Idiopathic facial aseptic granuloma - Facial nodule - Child - Inflammation
Rosacea
Journal
Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
02
08
2022
revised:
24
11
2022
accepted:
13
02
2023
medline:
25
9
2023
pubmed:
2
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
The primary objective was to study long-term outcomes in children with idiopathic facial aseptic granuloma (IFAG). The secondary objectives were to describe the clinical polymorphism of this entity, the different therapeutic options, and the occurrence of rosacea in this population. We selected patients with a clinical diagnosis of IFAG seen in two different hospitals in Normandy between March 2016 and February 2021, and we collected clinical and therapeutic data from computerized medical records. A remote consultation based on recent photographs was performed to collect new data, and the children's parents were asked to complete a questionnaire between February and August 2021. Ten children were included in this study. Nine patients presented with a single red to purplish nodule. One patient presented multiple papulopustular plaques. IFAG healed spontaneously without major sequelae, and this outcome was not influenced by any treatments. During follow-up, two patients developed childhood rosacea. Although some clinical heterogeneity exists, early diagnosis and follow-up of IFAG is necessary to avoid unnecessary topical or systemic antibiotic treatments that do not shorten the disease course. IFAG appears to be a possible mode of entry for infantile rosacea.
Identifiants
pubmed: 37263865
pii: S0151-9638(23)00033-9
doi: 10.1016/j.annder.2023.02.005
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-179Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.